Literature DB >> 25046154

Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.

Yali Qin1, Marisa Banasik1, SoonJeung Kim2, Adam Penn-Nicholson3, Habtom H Habte1, Celia LaBranche4, David C Montefiori4, Chong Wang5, Michael W Cho6.   

Abstract

One strategy being evaluated for HIV-1 vaccine development is focusing immune responses towards neutralizing epitopes on the gp120 outer domain (OD) by removing the immunodominant, but non-neutralizing, inner domain. Previous OD constructs have not elicited strong neutralizing antibodies (nAbs). We constructed two immunogens, a monomeric gp120-OD and a trimeric gp120-OD×3, based on an M group consensus sequence (MCON6). Their biochemical and immunological properties were compared with intact gp120. Results indicated better preservation of critical neutralizing epitopes on gp120-OD×3. In contrast to previous studies, our immunogens induced potent, cross-reactive nAbs in rabbits. Although nAbs primarily targeted Tier 1 viruses, they exhibited significant breadth. Epitope mapping analyses indicated that nAbs primarily targeted conserved V3 loop elements. Although the potency and breadth of nAbs were similar for all three immunogens, nAb induction kinetics indicated that gp120-OD×3 was superior to gp120-OD, suggesting that gp120-OD×3 is a promising prototype for further gp120 OD-based immunogen development.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIV-1; Neutralizing antibody; Outer domain; V3; Vaccine; gp120

Mesh:

Substances:

Year:  2014        PMID: 25046154      PMCID: PMC4125429          DOI: 10.1016/j.virol.2014.06.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  80 in total

1.  Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

Authors:  P D Kwong; R Wyatt; Q J Sattentau; J Sodroski; W A Hendrickson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Immune stimulating activity of two new chitosan containing adjuvant formulations.

Authors:  P G Seferian; M L Martinez
Journal:  Vaccine       Date:  2000-11-08       Impact factor: 3.641

Review 3.  HIV fusion and its inhibition.

Authors:  C C LaBranche; G Galasso; J P Moore; D P Bolognesi; M S Hirsch; S M Hammer
Journal:  Antiviral Res       Date:  2001-05       Impact factor: 5.970

Review 4.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-08       Impact factor: 5.217

5.  Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.

Authors:  Feng Gao; Eric A Weaver; Zhongjing Lu; Yingying Li; Hua-Xin Liao; Benjiang Ma; S Munir Alam; Richard M Scearce; Laura L Sutherland; Jae-Sung Yu; Julie M Decker; George M Shaw; David C Montefiori; Bette T Korber; Beatrice H Hahn; Barton F Haynes
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 6.  Glycoproteins from insect cells: sialylated or not?

Authors:  I Marchal; D L Jarvis; R Cacan; A Verbert
Journal:  Biol Chem       Date:  2001-02       Impact factor: 3.915

7.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 8.  GP120: target for neutralizing HIV-1 antibodies.

Authors:  Ralph Pantophlet; Dennis R Burton
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

9.  Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1.

Authors:  Xinzhen Yang; Vesko Tomov; Svetla Kurteva; Liping Wang; Xinping Ren; Miroslaw K Gorny; Susan Zolla-Pazner; Joseph Sodroski
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Authors:  Tongqing Zhou; Ling Xu; Barna Dey; Ann J Hessell; Donald Van Ryk; Shi-Hua Xiang; Xinzhen Yang; Mei-Yun Zhang; Michael B Zwick; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Joseph Sodroski; Richard Wyatt; Gary J Nabel; Peter D Kwong
Journal:  Nature       Date:  2007-02-15       Impact factor: 49.962

View more
  12 in total

1.  Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.

Authors:  Ujjwal Rathore; Mansi Purwar; Venkada Subramanian Vignesh; Raksha Das; Aditya Arun Kumar; Sanchari Bhattacharyya; Heather Arendt; Joanne DeStefano; Aaron Wilson; Christopher Parks; Celia C La Branche; David C Montefiori; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2018-08-09       Impact factor: 5.157

2.  Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.

Authors:  Saikat Banerjee; Heliang Shi; Marisa Banasik; Hojin Moon; William Lees; Yali Qin; Andrew Harley; Adrian Shepherd; Michael W Cho
Journal:  Virology       Date:  2017-02-23       Impact factor: 3.616

3.  Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Authors:  Samantha Townsley; Zeinab Mohamed; Wenjin Guo; Jennifer McKenna; Brad Cleveland; Celia LaBranche; David Beaumont; Xiaoying Shen; Nicole L Yates; Abraham Pinter; Georgia D Tomaras; Guido Ferrari; David C Montefiori; Shiu-Lok Hu
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

4.  Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.

Authors:  Saikat Banerjee; Heliang Shi; Habtom H Habte; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2016-01-21       Impact factor: 3.616

5.  Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.

Authors:  Habtom H Habte; Saikat Banerjee; Heliang Shi; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2015-10-09       Impact factor: 3.616

6.  Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop.

Authors:  Yali Qin; Saikat Banerjee; Aditi Agrawal; Heliang Shi; Marisa Banasik; Feng Lin; Kari Rohl; Celia LaBranche; David C Montefiori; Michael W Cho
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

7.  Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits.

Authors:  Yali Qin; Heliang Shi; Saikat Banerjee; Aditi Agrawal; Marisa Banasik; Michael W Cho
Journal:  Retrovirology       Date:  2014-12-20       Impact factor: 4.602

8.  Transient Biocompatible Polymeric Platforms for Long-Term Controlled Release of Therapeutic Proteins and Vaccines.

Authors:  Handan Acar; Saikat Banerjee; Heliang Shi; Reihaneh Jamshidi; Nastaran Hashemi; Michael W Cho; Reza Montazami
Journal:  Materials (Basel)       Date:  2016-04-28       Impact factor: 3.623

Review 9.  Native-like Env trimers as a platform for HIV-1 vaccine design.

Authors:  Rogier W Sanders; John P Moore
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 10.  HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth.

Authors:  Jelle van Schooten; Marit J van Gils
Journal:  Retrovirology       Date:  2018-11-26       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.